Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Mankind Pharma Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,053 | 2,579 | 2,708 | 2,607 | 2,422 | 2,868 | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 |
| Expenses + | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 |
| Operating Profit | 417 | 655 | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 |
| OPM % | 20% | 25% | 25% | 23% | 24% | 23% | 28% | 26% | 22% | 24% | 25% | 26% | 27% |
| Other Income + | 50 | 63 | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 |
| Interest | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 |
| Depreciation | 85 | 87 | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 |
| Profit before tax | 377 | 624 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 |
| Tax % | 22% | 21% | 20% | 18% | 17% | 18% | 22% | 22% | 17% | 18% | 17% | 19% | 15% |
| Net Profit + | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 |
| EPS in Rs | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.22 | 10.20 | 10.62 | 12.39 | 9.90 | 13.43 |
Financials of Mankind Pharma Ltd
Annual income statement trend
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 3,334 | 5,865 | 6,214 | 7,782 | 8,749 | 10,260 | 12,207 | 14,278 |
| Expenses + | 2,748 | 4,427 | 4,565 | 5,791 | 6,848 | 7,743 | 9,182 | 10,660 |
| Operating Profit | 586 | 1,438 | 1,649 | 1,991 | 1,902 | 2,517 | 3,026 | 3,617 |
| OPM % | 18% | 25% | 27% | 26% | 22% | 25% | 25% | 25% |
| Other Income + | 76 | 122 | 183 | 210 | 141 | 295 | 548 | 241 |
| Interest | 2 | 23 | 21 | 60 | 46 | 34 | 432 | 639 |
| Depreciation | 39 | 99 | 119 | 167 | 326 | 378 | 621 | 886 |
| Profit before tax | 621 | 1,438 | 1,692 | 1,975 | 1,671 | 2,399 | 2,521 | 2,333 |
| Tax % | 29% | 27% | 24% | 26% | 22% | 19% | 20% | 17% |
| Net Profit + | 445 | 1,056 | 1,293 | 1,453 | 1,310 | 1,942 | 2,011 | 1,938 |
| EPS in Rs | 219.33 | 25.72 | 31.59 | 35.78 | 32.00 | 47.75 | 48.26 | 46.34 |
| Dividend Payout % | 0% | 0% | 24% | 0% | 0% | 0% | 0% | 0% |
Financials of Mankind Pharma Ltd
Capital structure and asset base
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
| Reserves | 2,035 | 3,445 | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 |
| Borrowings + | 0 | 131 | 241 | 873 | 170 | 207 | 8,511 | 6,312 |
| Other Liabilities + | 968 | 1,449 | 1,397 | 2,080 | 2,080 | 2,313 | 4,808 | 5,468 |
| Total Liabilities | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 28,080 |
| Fixed Assets + | 316 | 1,600 | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 19,093 |
| CWIP | 47 | 317 | 372 | 701 | 550 | 282 | 826 | 655 |
| Investments | 959 | 829 | 1,512 | 1,109 | 1,346 | 2,568 | 2,042 | 1,985 |
| Other Assets + | 1,700 | 2,319 | 2,811 | 3,709 | 3,538 | 4,488 | 5,780 | 6,346 |
| Total Assets | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 28,080 |
Financials of Mankind Pharma Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 | 3,121 | |
| Cash from Investing Activity + | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 | -196 | |
| Cash from Financing Activity + | -531 | -8 | 605 | -740 | 5 | 10,233 | -2,953 | |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 | -28 | |
| Free Cash Flow | 853 | 826 | -1,423 | 987 | 1,771 | 1,895 | 2,387 | |
| CFO/OP | 97% | 96% | 71% | 112% | 103% | 98% | 103% |
Financials of Mankind Pharma Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 33 | 19 | 18 | 24 | 30 | 46 | 44 |
| Inventory Days | 166 | 175 | 243 | 265 | 188 | 180 | 219 | 193 |
| Days Payable | 71 | 145 | 137 | 162 | 126 | 90 | 119 | 121 |
| Cash Conversion Cycle | 117 | 63 | 125 | 121 | 86 | 120 | 146 | 117 |
| Working Capital Days | 56 | 30 | 32 | 24 | 39 | 53 | -28 | -1 |
| ROCE % | 37% | 32% | 22% | 26% | 16% | 14% |